Tempus AI, Inc.
No SEC Form 4 filings for $TEM in the last 30 days.
Tempus AI (TEM) launched ArteraAI Prostate Test, described by the company as the first externally developed digital pathology algorithm. The article also discusses broader AI investment themes and promotional newsletter offers, but provides no additional financial results or guidance for Tempus AI.
Tempus AI (NASDAQ: TEM) successfully completed a private offering of $460 million in 0.00% Convertible Senior Notes due 2032. The company used approximately $307.7 million of the net proceeds to repay outstanding loans under its senior secured credit facilities and allocated $31.2 million for capped call transactions. The remaining funds are intended for general corporate purposes, including potential acquisitions and strategic investments.
Tempus AI (TEM) CEO Eric Lefkofsky's entities, Blue Media, LLC and Gray Media, LLC, indirectly sold a total of 166,250 shares of Class A Common Stock. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025, with weighted-average prices around $51 per share. Despite these sales, Lefkofsky maintains significant indirect and direct holdings in the company.
